Investor Backing & Capital Strength:
Recent funding rounds (Series B in 2022 and an additional $10M in Dec 2024) extended capital runway into 2025–2026. Feedback suggests this supports continued product and commercial investment rather than retrenchment.
Product Line Growth:
New offerings like Signal alerts (2025) and an AI discharge summary (2026) indicate an active shipping cadence. Feedback suggests the roadmap is expanding beyond raw data access into alerts and AI‑driven summaries.
Market Expansion:
Connectivity spans Carequality, CommonWell, eHealth Exchange and select state HIEs with claims of 320M+ patient records accessible. Feedback suggests ongoing investment in breadth and depth of connections.
